Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …

Lung cancer causes significant morbidity and mortality in China and worldwide. In China,
lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer …

The ɛ4 allele of the apolipoprotein E (APOE) gene is currently the strongest and most highly
replicated genetic factor for risk and age of onset of late-onset Alzheimer's disease (LOAD) …

Background Tubal ectopic pregnancies can cause substantial morbidity or even death.
Current treatment is with methotrexate or surgery. Methotrexate treatment fails in …

Previous studies have demonstrated a significant difference in clinical characteristics
between patients with non‑small cell lung cancer (NSCLC) harboring exon 19 deletion (19 …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

INTRODUCTION: A feasibility study was performed to examine the safety and toxicity profile
of daily gefitinib (250mg) administration with concurrent definitive thoracic radiation therapy …

In the past decade, molecular-targeted drugs have been focused upon for the treatment of
cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase …

The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly
improved overall survival in the first-line treatment of patients with advanced non-small cell …

Gefitinib (Iressa, AstraZeneca) has been widely used for the treatment of locally advanced or
metastatic non-small cell lung cancer. A number of studies have been reported on its …